Product Description
Dexchlorpheniramine is an alkylamine, and first-generation histamine antagonist with anti-allergic activity. Dexchlorpheniramine competitively blocks H1 receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries and gastrointestinal (GI) smooth muscle. The antagonistic action of this agent blocks the activities of endogenous histamine, thereby preventing histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms. Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dexchlorpheniramine)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Brazil | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | France | Hong Kong | India | Indonesia | Italy | Jordan | Korea | Lebanon | Malaysia | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Singapore | Slovenia | South Africa | Spain | Sweden | Taiwan | Tunisia | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|